InMed Shares Trade Up 25% After Becoming First to Advance Cannabinol into Clinical Trials

  ()
InMed Pharmaceuticals shares traded 25% higher after reporting that it is the first to advance cannabinol into therapeutic clinical trials. read more >

NantKwest Shares Jump More than 50% Following JP Morgan Healthcare Conference Presentation

  ()
Shares of NantKwest Inc. spiked as much as 85% higher, setting a new 52-week high price, after the company reported a series of positive results at the 38th JP Morgan Healthcare Conference in San Francisco. The firm reported that complete responses were noted in as many as six different multiple tumor types when "natural killer" cells and T cells are activated simultaneously. read more >

Biotech Announces Deal with Bayer on Non-Hormonal Contraception

Research Report
  ()
Details of the arrangement and an update on the company's pipeline are provided in a Dawson James report. read more >

Transenterix Shares Trade Up 25% on FDA Filing for First Machine Vision System in Robotic Surgery

  ()
Shares of Transenterix opened 50% higher after the company reported that it has submitted a 510(k) submission to the FDA for the first machine vision system for use in robotic surgery. read more >
News Update

Healthcare Company Closes Acquisition of Telehealth Firm

News Update
  ()
The transaction brings numerous existing partnerships and digital technologies. read more >

Two Analysts See Company as a Buy for 'Game-Changing' Potential in Bladder Cancer Detection and Surgery

  ()
The disruptive technology is 'poised to deliver significant advancement in bladder cancer detection.' read more >

Disruptive Technology Poised to Deliver Significant Advancement in Bladder Cancer Detection

Contributed Opinion
  ()
Chris Temple, editor and publisher of The National Investor, explains why he recommends this small-cap as a Buy. read more >

Adaptimmune Shares Triple as SPEAR T-cell Platform Delivers Initial Responses in Four Solid Tumor Indications

  ()
Shares of Adaptimmune Therapeutics more than tripled in value after the company reported that its SPEAR T-cell platform delivered positive initial responses in four different solid tumor indications. read more >

Ultragenyx Shares Increase 30% on Results from Phase 1/2 OTC Deficiency Study

  ()
Rare disease biopharmaceutical company Ultragenyx Pharmaceutical's shares traded 30% higher after the firm reported positive topline results from Cohorts 2 and 3 in its Phase 1/2 study of DTX301 gene therapy in Ornithine Transcarbamylase Deficiency. read more >
News Update

Life Sciences Firm Upgrades to OTCQB Venture Market

News Update
  ()
This is a significant achievement of this developing company. read more >

Expert Investing Ideas

"DRRX earned a $10M milestone payment from Gilead."

–Ed Arce, H.C. Wainwright & Co.


"The market for DRRX's POSIMIR could be substantial."

–Brian Marckx, Zacks Small-Cap Research


Learn More about Which Online Broker is Right for You?

Get Our Streetwise Reports Life Sciences Report Newsletter Free and be the first to know!

A valid email address is required to subscribe
NASDAQ Biotech ARCA Pharmaceutical
News Update

Telemedicine Tech Firm Garners Five New US Clients

News Update
  ()
With these contracts, the company extends its geographic footprint to an additional county. read more >
News Update

Developer Completes Design Verification of Imaging Device for Bladder Cancer

News Update
  ()
In doing so, it gets one step closer to market approval from U.S. regulators. read more >

Applied Genetic Tech's Shares Double on 6-Month X-Linked RP Study Results

  ()
Shares of Applied Genetic Technologies skyrocketed to a new 52-week high price after the company reported positive six-month data from its ongoing Phase 1/2 clinical study for treatment in X-Linked Retinitis Pigmentosa. The firm stated that the trial data suggests durable and meaningful improvements in central visual sensitivity and advised that it plans to initiate a pivotal trial by year-end 2020. read more >

Applied Therapeutics Investors Like the ACTION in Phase 2 Galactosemia Study

  ()
Applied Therapeutics' shares traded 25% higher after the company reported positive topline results from its Pivotal Phase 2 ACTION Study of AT-007 for use in the treatment of galactosemia. The firm expects to file for regulatory approval of AT-007 in H2/20. read more >